Briacell Therap Q4 2024 Earnings Report

Briacell Therap EPS Results

• Actual EPS: -$10.50
• Consensus EPS: -$78.00
• Beat/Miss: Beat by +$67.50
• One Year Ago EPS: N/A

Briacell Therap Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Briacell Therap Announcement Details

• Quarter: Q4 2024
• Date: 10/28/2024
• Time: TAS
• Conference Call Date: N/A
• Conference Call Time: N/A

Briacell Therap (NASDAQ:BCTX)eutics Corp. (NASDAQ:BCTX) is a biotechnology company focused on developing targeted immunotherapies for cancer. The company’s research centers on cell-based therapies designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on difficult-to-treat solid tumors.

BriaCell’s lead technology, Bria-IMT, is an immunotherapy derived from a proprietary breast cancer cell line. The company has studied Bria-IMT in patients with advanced or metastatic breast cancer, including in combination with immune checkpoint inhibitors. BriaCell has also been developing Bria-OTS, an off-the-shelf cell-based immunotherapy intended to provide a more broadly available treatment option without requiring an individualized product for each patient.

Founded in 2006, BriaCell is a Canadian biotechnology company with operations in North America. Its programs have primarily focused on advanced breast cancer, while the company has also explored broader applications of its immunotherapy platform in other solid tumors. William Williams has served as the company’s president and chief executive officer.